Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

This publication has 20 references indexed in Scilit:

• Tolcapone added to levodopa in stable parkinsonian patients: A double‐blind placebo‐controlled study
  Movement Disorders, 1997
• Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
  Journal of Neurology, Neurosurgery & Psychiatry, 1997
• Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly*
  Clinical Pharmacology & Therapeutics, 1997
• Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
  Neurology, 1997
• Efficacy and safety of tolcapone in levodopa‐treated Parkinson's disease patients with “wearing‐off” phenomenon: a multicentre, double‐blind, randomized, placebo‐controlled trial
  European Journal of Neurology, 1997
• Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations
  Neurology, 1997
• Multiple-dose clinical pharmacology of the catechol- O -methyl-transferase inhibitor tolcapone in elderly subjects
  European Journal of Clinical Pharmacology, 1996
• Pharmacokinetic‐pharmacodynamic interaction between the COMT inhibitor tolcapone and single‐dose levodopa.
  British Journal of Clinical Pharmacology, 1995
• Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans*
  Clinical Pharmacology & Therapeutics, 1995
• Should clearance be normalised to body surface or to lean body mass?
  British Journal of Clinical Pharmacology, 1981